The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Quick Facts
What This Study Found
Lu-177-DOTATATE showed a median progression-free survival of 28.4 months compared to 8.5 months for octreotide LAR.
Key Numbers
How They Did This
The study reviews clinical trials and ongoing research comparing different treatment approaches for NETs.
Why This Research Matters
These advancements in PRRT could significantly improve treatment outcomes for patients with neuroendocrine tumors, offering new hope for better management of the disease.
What This Study Doesn't Tell Us
The study primarily reviews existing data and ongoing trials, lacking direct experimental results from new therapies.
Trust & Context
- Original Title:
- The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
- Published In:
- Frontiers in endocrinology, 13, 941832 (2022)
- Authors:
- Harris, Philip E, Zhernosekov, Konstantin
- Database ID:
- RPEP-06172
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06172APA
Harris, Philip E; Zhernosekov, Konstantin. (2022). The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?. Frontiers in endocrinology, 13, 941832. https://doi.org/10.3389/fendo.2022.941832
MLA
Harris, Philip E, et al. "The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?." Frontiers in endocrinology, 2022. https://doi.org/10.3389/fendo.2022.941832
RethinkPeptides
RethinkPeptides Research Database. "The evolution of PRRT for the treatment of neuroendocrine tu..." RPEP-06172. Retrieved from https://rethinkpeptides.com/research/harris-2022-the-evolution-of-prrt
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.